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Abstract
Nasopharyngeal carcinoma (NPC) is a rare malignancy in most part of the world and it is
one of the most confusing, commonly misdiagnosed and poorly understood diseases. The
cancer is an Epstein-Barr virus-associated malignancy with a remarkable racial and
geographical distribution. It is highly prevalent in southern Asia where the disease occurs at
a prevalence about a 100-fold higher compared with other populations not at risk. The
etiology of NPC is thought to be associated with a complex interaction of genetic, viral,
environmental and dietary factors. Thanks to the advancements in genomics, proteomics
and bioinformatics in recent decades, more understanding of the disease etiology,
carcinogenesis and progression has been gained. Research into these components may
unravel the pathways in NPC development and potentially decipher the molecular
characteristics of the malignancy. In the era of molecular medicine, specific treatment to the
potential target using technologies such as immunotherapy and RNAi becomes formulating
from bench to bedside application and thus makes molecular biomarker discovery more
meaningful for NPC management. In this article, the latest molecular biomarker discovery
and progress in NPC is reviewed with respect to the diagnosis, monitoring, treatment and
prognostication of the disease.
Background
Nasopharyngeal carcinoma (NPC) is a disease in which
malignant cells form in the tissues of the nasopharynx. As
one of the most common cancers among Chinese or Asian
ancestry, it poses one of the serious health problems in
southern China where an annual incidence of more than
20 cases per 100,000 is reported. Men are twice as likely to
develop NPC as women. The rate of incidence generally
increases from ages 20 to around 50. Signs and symptoms
at presentation include painless, enlarged cervical lymph
nodes, nasal obstruction, epistaxis, diminished hearing,
tinnitus, recurrent otitis media, cranial nerve dysfunction,
sore throat and headache. According to the tumour-node-
metastasis staging system promulgated by the American
Joint Committee on Cancer, patients are designated into
stages 0, I, IIA, IIB, III, IVA, IVB and IVC.
Molecular biomarkers in etiology
Factors thought to predispose to NPC include ethnic back-
ground, Epstein-Barr virus (EBV) exposure and consump-
tion of food with volatile nitrosamines [1]. It was found
that the polymorphism of a nitrosamine metabolizing
gene, CYP2A6, might play a crucial role in NPC suscepti-
bility and it might be used as a risk marker for NPC [2].
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In the most prevalent area, a lot of genetic polymorphism
of CYP2F1 gene is found in Guangdong population of
China. When the genetic polymorphism of CYP2F1 was
investigated, the cooperated operations with multiple
genetic polymorphisms of one or more genes were found
to be potential critical factors contributing to the develop-
ment and progression of NPC [3]. On the other hand, the
XRCC1 gene is important in DNA base excision repair. It
was hypothesized that two common single nucleotide
polymorphisms of XRCC1 (codons 194 Arg → Trp and
399 Arg → Gln) were related to the risk of NPC and inter-
acted with tobacco smoking. The XRCC1 Trp194Trp vari-
ant genotype was found to be associated with a reduced
risk of developing NPC in Guangdong population, partic-
ularly in males and smokers [4]. On the other hand, Cyclin
D1 (a key regulator of the cell cycle) and its altered activity
associated with the development of cancer has been stud-
ied in a low-risk country. The proportion of NPC cases
attributable to the GG Cyclin D1 genotype was 15% in
Portuguese patients with NPC. This result might be
important in the definition of a biologic predictive profile
for the development of NPC within the Portugal popula-
tion [5].
Molecular biomarkers of carcinogenesis
NPC is a complex disease caused by an interaction of EBV
chronic infection, environment and host genes, in a
multi-step process of carcinogenesis. Genomic instability
can be an early event marker in carcinogenesis of NPC.
Aggravation of genomic alterations is also a poor progno-
sis for cancer recovery [6]. For understanding the putative
order of genetic alteration in NPC carcinogenesis, evolu-
tionary tree models (branching and distance-based tree
models) were used to analyze comparative genomic
hybridization data of NPC cases. Chromosome 12 gain
and consistent loss of 3p for both tree models were impor-
tant early events in NPC progression. The tree models sug-
gested two subclasses of 3p-derived NPC, one marked by
1q+, 9p- and 13q-, and the other marked by 14q-, 16q-,
9q- and 1p- [7].
Using bioinformatics to analyze the expression and loca-
tion of UBAP1 protein, it was found that EGFP/UBAP1
was expressed and existed mainly in the nuclear, espe-
cially accumulated on the nuclear envelope. The expres-
sion difference in NPC cells might be related to the
carcinogenesis of NPC [8]. Moreover, a locus on 3p21 was
identified to link to NPC in a linkage analysis [9].
RASSF1A  is a tumour suppressor gene on 3p21.3 fre-
quently inactivated by promoter hypermethylation in
NPC. Investigated by high-density oligonucleotide array,
the expressions of activin βE and Id2 in NPC were tightly
regulated by RASSF1A.  RASSF1A-induced repression of
Id2 was mediated by the overexpression of activin βE. The
results suggested a novel RASSF1A pathway in which both
activin βE and Id2 were involved [10].
A new carcinoma-related gene named KIAA1173 locating
at 3p22.1 was also characterized. It was strongly expressed
in normal nasopharyngeal mucosa epithelia, but down-
regulated in NPC. KIAA1173 might be associated with the
carcinogenesis of NPC [11]. In a study using microdissec-
tion and cDNA microarray, gene expression patterns sug-
gested the dysregulation of the GTP/GDP-bound Ras cycle
and an abnormal hyperactivity of cell cycle in NPC. Alter-
ations in the Wingless-type (Wnt) pathway suggested that
this pathway might be activated in NPC [12]. On the other
hand, elevation of plasma osteopontin level was found in
patients with undifferentiated NPC. The finding indicated
a potential role of osteopontin in the pathogenesis and
nodal metastasis of undifferentiated NPC [13].
Molecular diagnostic biomarkers
Diagnosis is made by biopsy of the nasopharyngeal mass.
Fused positron emission tomography/computed tomog-
raphy is a valuable imaging tool in patients for staging
diagnosis of NPC. However, NPC is commonly diagnosed
late due to its deep location and vague symptoms [14]. By
measuring the nuclear DNA content, DNA diploidy was
found to occur earlier in the progression from premalig-
nant to malignant head and neck squamous cell carcino-
mas (including NPC). This finding was promising to
demonstrate methods that were readily applicable for rou-
tine diagnostic work [15]. Elevated RNase activity has pre-
viously been described in the circulation of cancer
patients, and NPC was found to be associated with distur-
bances in the integrity of cell-free circulating RNA. Meas-
urement of plasma RNA integrity might serve as a useful
marker for the diagnosis and monitoring of NPC [16].
It has been reported that the high sensitivity (81%) and
specificity (0% false positives) of detecting aberrant meth-
ylation of CDH13 (encoded a cell adhesion molecule H-
cadherin) from nasopharyngeal swabs suggested it could
be utilized as a tool for early diagnosis [17]. Systematically
identified by sodium dodecyl sulfate polyacrylamide gel
electrophoresis combined with matrix-assisted laser des-
orption/ionization time-of-flight mass spectrometry and
further confirmed by Western blot analysis in the NPC
cell-lines, fibronectin, Mac-2 binding protein and plas-
minogen activator inhibitor 1 were found to be potential
markers for diagnosis of NPC [18] (Table 1).
Molecular biomarkers of targeted therapies
High-dose radiotherapy with adjunctive chemotherapy is
the primary treatment of NPC [19]. Surgery, when feasi-
ble, is usually reserved for nodes that fail to regress after
radiotherapy and chemotherapy, or for nodes that recur-
rent following clinical complete response. RadiotherapyMolecular Cancer 2007, 6:1 http://www.molecular-cancer.com/content/6/1/1
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dose and field margins are individually tailored to the
location and size of the primary tumour and lymph nodes
[20,21]. New types of treatment are being tested in clinical
trials, which include biological therapy and intensity-
modulated radiation therapy. Advances in immunologic
research and combined chemotherapy offer hope for bet-
ter control of the disease [22].
Using oligonucleotide microarray analysis mapping close
to a previously defined 11q22-23 NPC critical region,
THY1 showed consistent downregulated expression in the
tumour segregants. THY1 was identified to be a candidate
tumour suppressor gene significantly associated with
lymph node metastatic NPC [23]. Employing the mono-
chromosome transfer approach, it was shown that chro-
mosome 3p could suppress tumour growth in vivo. By
quantitative reverse transcription polymerase chain reac-
tion (PCR), a candidate tumour suppressor gene BLU/
ZMYND10 mapping in the 3p21.3 critical region, was fre-
quently downregulated in NPC cell lines and NPC biop-
sies [24]. Another tumour suppressor gene DLC-1,
locating at the human chromosome region 8p22, is fre-
quently deleted in NPC. The mRNA level of DLC-1 was
found to be downregulated in NPC. To identify the mech-
anism of DLC-1 downregulation, the methylation status
of  DLC-1  was investigated using methylation-specific
PCR. Results showed that DLC-1 might be a NPC-related
tumour suppressor gene affected by aberrant promoter
methylation and gene deletion [25].
Stress-responsive gene GADD45G was found to be a func-
tional new-age tumour suppressor, with its response to
environmental stresses frequently disrupted epigeneti-
cally in NPC [26]. Another study suggested that a novel
bromodomain gene, BRD7, was identified to be associ-
ated with NPC. Overexpression of BRD7  could inhibit
NPC cell growth and arrest cells in cell cycle by transcrip-
tionally regulating some important molecules involved in
ras/MEK/ERK and Rb/E2F pathway, and downregulate the
promoter activity of E2F3. The nuclear localization of
BRD7 was critical for the expression of cell cycle related
molecules and cell biological function [27]. Using colony
formation assay, Cheung et al found a suppression of
human MAD2B conferred hypersensitivity to a range of
DNA-damaging agents, especially DNA cross-linkers, such
as cisplatin and gamma-irradiation. The result indicated
that cancer cells were sensitized to DNA-damaging anti-
cancer drugs through inactivation of MAD2B in NPC [28].
Constitutive activation of Wnt signaling and WIF-1 silenc-
ing was found in NPC cell lines. Utilizing methylation-
specific PCR and sequence analysis, frequent hypermeth-
ylation of the WIF-1  promoter correlated with WIF-1
silencing was demonstrated in NPC cell lines. These
results indicated that aberrant Wnt signaling was a com-
mon event in NPC carcinogenesis linked with WIF-1
silencing in cell lines. Strategies targeting these molecules
might be potentially promising in treating NPC [29]. The
14-3-3σ gene product, up-regulated by p53 in response to
DNA damage, is involved in cell-cycle checkpoint control
and is a human cancer epithelial marker downregulated in
various tumours. It was reported that overexpression of
14-3-3σ in NPC cell lines reduced the tumour volume in
nude mice. This finding provided an insight into the role
of 14-3-3σ in NPC and suggested that modulating 14-3-
3σ activity might be useful in the treatment of NPC [30].
Using immunohistochemical streptomycin-avidin peroxi-
dase staining and terminal deoxynucleotidyl transferase
mediate dUTP nick and labeling technique, He and Kong
demonstrated that the expression of effector cell protease
receptor-1 played a role in increase the apoptosis and
decrease the proliferation of cell in NPC. This suggested
that effector cell protease receptor-1 might be a potential
therapy for NPC [31]. Death-associated protein kinase
(DAPK) is a Ca/calmodulin-regulated serine/threonine
kinase and a positive mediator of apoptosis. Loss of DAPK
expression was shown to be associated with promoter
region methylation in NPC. A demethylating agent, 5-
Aza-2'-deoxycytidine, might slow the growth of NPC cells
in vitro and in vivo by reactivating the DAPK gene silenced
by de novo methylation [32]. The antiapoptotic gene bcl-2
Table 1: Biomarkers identified by proteomics technologies in nasopharyngeal carcinoma
Technology Primary use Biomarker
Two-dimensional electrophoresis and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry
Diagnosis Fibronectin, Mac-2 binding protein, Plasminogen 
activator inhibitor 1
Signaling target Annexin A2, Heat shock protein 27, Stathmin, 
Annexin I, Basic transcription factor 3, Porin
Treatment response monitoring Ceruloplasmin
Surface-enhanced laser desorption/ionization time-of-flight 
mass spectrometry and tandem mass spectrometry
Diagnosis Inter-α-trypsin inhibitor precursor
Treatment response monitoring Platelet factor-4
Prognosis Serum amyloid AMolecular Cancer 2007, 6:1 http://www.molecular-cancer.com/content/6/1/1
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antisense oligodeoxynucleotide, G3139, was found to
have proapoptotic effects in C666-1 cell line. Combining
with cisplatin, it was curative in C666-1 NPC xenograft
tumours in vivo. The sequence-dependency of these effects
was consistent with an antisense mechanism. The result
suggested that bcl-2 might represent a biologically relevant
target for the development of novel combinatorial thera-
pies for NPC [33].
The discovery of RNA interference (RNAi) gene silencing
by double-stranded RNA earned the Nobel Prize in Phys-
iology or Medicine in 2006 and led the treatment of dis-
ease to a new horizon. The transient transfected bcl-xL
siRNA4 could effectively inhibit the growth of the cancer
cells and induce their apoptosis. Knockdown of bcl-xL
expression with RNAi induced NPC cells apoptosis, sug-
gesting that the siRNA technique could provide a new
method for anti-NPC gene therapy [34]. Epidermal
growth factor receptor silencing by RNAi could reduce the
proliferation of NPC cells and induce cell cycle arrest at
G1 phase, which shed light on the possible use of RNAi
for further investigation of the pathogenesis and gene
therapy of NPC [35]. Pathway analyses by microarrays
revealed that upregulation of NF-κB2 and survivin played
central roles in increasing resistance to apoptosis, as well
as changes in integrin and Wnt/β-catenin signaling lead-
ing to uncontrolled proliferation. The role of survivin in
resisting apoptosis in NPC was confirmed by RNAi, which
suggested survivin as a novel therapeutic target for NPC
[36].
Molecular biomarkers for treatment response 
monitoring
Major factors adversely influencing outcome of treatment
include large size of the tumour, advanced tumour stage
and the presence of involved cervical lymph nodes
[37,38]. The DNA anueploid content in NPC was found to
be positively related to the S phase cells by flow cytometric
analysis. Patients having a low expression of Ki67 or DNA
aneuploid in tumour cells were not sensitive to chemo-
therapy, liable to metastasis to distant organs and had a
poor prognosis. It was suggested that DNA ploidy and
Ki67 could be used as an independent and objective
marker to evaluate the radiosensitivity and prognosis of
NPC [39]. The changes of serum vascular endothelial
growth factor (VEGF) before and after radiotherapy in
NPC patients were studied. Zhao et al reported that
patients with high serum VEGF level were found to have a
poor prognosis [40]. Endothelin-1 is a potent vasoactive
peptide and a hypoxia-inducible angiogenic growth factor
associated with the development and spread of solid
tumours. Pretreatment plasma big endothelin-1 levels
might be useful in predicting posttreatment distant failure
in patients with advanced-stage NPC [41].
Ceruloplasmin (CPL) was identified as a potential serum
biomarker by mass spectrometric analysis and MASCOT
database search. The enhanced expression of CPL in the
NPC patients' sera was confirmed by competitive enzyme-
linked immunosorbent assay (ELISA). When follow-up
two-dimensional electrophoresis and ELISA studies were
performed on the NPC patients who responded positively
to treatment, the difference in CPL expression was no
longer significant [42] (Table 1).
Using proteinchip profiling analysis, two isoforms of
serum amyloid A (SAA) protein were identified as useful
biomarkers to monitor relapse of NPC. Monitoring the
patients longitudinally for SAA level by proteinchip and
validated by immunoassay showed a dramatic SAA
increase, which correlated with relapse and a drastic fall
correlated with response to salvage chemotherapy [43].
Further examination was conducted to found other serum
biomarkers that were associated with active disease or
chemotherapy response in NPC patients treated by two
different drug combinations. Using tandem MS sequenc-
ing and immunoaffinity capture assay, two potential
biomarkers were identified as a fragment of inter-α-
trypsin inhibitor precursor and platelet factor-4. These
disease and treatment associated serum biomarkers might
serve to diagnose and triage NPC patients for appropriate
chemotherapy treatment respectively [44] (Table 1).
Molecular biomarkers for prognosis and 
progression of cancer
Small cancers of the nasopharynx are highly curable by
radiotherapy with chemotherapy and have shown sur-
vival rates of 80% to 90% [45]. Moderately advanced
lesions without clinical evidence of spread to cervical
lymph nodes are often curable and have shown survival
rates of 50% to 70%. Patients with advanced lesions, espe-
cially those associated with clinically positive cervical
lymph nodes, cranial nerve involvement and bone
destruction, are poorly controlled locally by radiotherapy
with or without surgery and often develop distant metas-
tases despite local control [46,47]. Although most recur-
rences occur within five years of diagnosis, relapse can be
seen at longer intervals [48].
It has been reported that average expression of Tiam1 in
NPC tissue was higher than in normal nasopharyngeal tis-
sue. This data suggested that the overexpression of the
Tiam1 correlated invasion and metastasis of NPC [49].
Interleukin IL-8 receptor A was demonstrated to be over-
expressed in tumour cells and correlated significantly with
angiogenesis in NPC. The result suggested that the expres-
sion of IL-8 receptor A in tumour cells might be an impor-
tant indicator of poor prognosis in NPC [50]. The positive
gradual expression of estrogen and progestogen receptors
in NPC was well correlated with distant metastasis. StrongMolecular Cancer 2007, 6:1 http://www.molecular-cancer.com/content/6/1/1
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positive expression pointed out bad prognosis and endo-
crine treatment might reduce and postpone distant metas-
tasis [51]. Adopting immunohistochemistry labeled
streptavidin biotin method, overexpression of epidermal
growth factor receptor and phosphorylated extracellular
signal-regulated kinase was detected in NPC. The abnor-
mally high expression signified poor prognosis in NPC
patients [52].
VEGF expression was assessed in NPC and benign ade-
noid lesions by immunohistochemistry and EBV presence
by PCR using primers directed against EBV nuclear anti-
gen EBNA-1. The results pointed towards the potential of
the expression pattern of VEGF as a tumour marker for the
early diagnosis of metastatic NPC and also showed that
presence of EBV was related to up regulation of VEGF [53].
An immunohistochemistry study found that VEGF and its
receptors fms-like tyrosine kinase-1 and kinase insert
domain containing receptor were widely expressed in
NPC tissues. Their expressions were positively related to
clinical features and prognosis of NPC patients [54]. The
expressions of nm23-H1 and VEGF protein were exam-
ined by immunohistochemistry S-P staining in NPC tis-
sues. The low level expression of nm23-H1 protein and
the high level expression of VEGF protein might be asso-
ciated with the development and poor prognosis of NPC
[55].
NPC samples expressed high levels of survivin and livin,
which might play an important role in the oncogenesis
and tumour development. Overexpression of survivin was
related with poor prognosis, suggesting that the determi-
nation of survivin expression might provide predictive
information on NPC patients [56]. It has been reported
that high Bmi-1 oncoprotein expression was found to be
positively correlated with poor prognosis of NPC patients.
This finding suggested that Bmi-1 played an important
role in the development and progression of NPC, and that
it was a valuable marker for assessing the prognosis of
NPC patients [57]. Immunohistochemistry was per-
formed on formalin-fixed paraffin-embedded sections of
patients with NPC. Bar-Sela et al found that heparanase
expression was inversely correlated with survival of NPC
patients, clearly indicating that heparanase was a reliable
prognostic factor for this malignancy [58].
Molecular biomarkers of Epstein-Barr virus-
associated nasopharyngeal carcinoma
EBV is an oncogenic human gamma-herpesvirus that per-
sistently infects more than 90% of the human population.
There are compelling evidences suggesting that EBV is a
causal agent of NPC and is most likely to be involved in
the multi-step and multi-factorial development of the
cancer. EBV encoded genes have been shown to be
involved in immune evasion and in the regulation of var-
ious cellular signaling cascades. The fact that EBV genome
is present in almost all NPC tissues renders it an ideal
tumour marker for NPC. Quantitative analyses of EBV
antibodies and EBV DNA have been shown to be clinically
useful for the early detection, monitoring and prognosti-
cation of NPC.
Assessment of immunoglobulin A (IgA) and immu-
noglobulin G (IgG) antibodies responses to various EBV
antigen complexes, usually involving multiple serological
assays, is important for the early diagnosis of NPC. EBNA-
1, the viral protein uniformly expressed in NPC, repre-
sents a prime target for T-cell based immunotherapy [59].
Through combination of two synthetic peptides repre-
senting immunodominant epitopes of EBNA-1 and viral
capsid antigen VCA-p18, a one-step sandwich ELISA for
the specific detection of EBV reactive IgA and IgG antibod-
ies in NPC patients was developed [60]. Comparing the
antibody levels to VCA of EBV as potential diagnostic
markers of NPC, VCA-IgA had an advantage over VCA-IgG
despite the slightly lower sensitivity due to its consistently
more distinct fluorescence reaction [61]. In a combina-
tion of the surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry serum protein profiles
with EBNA-1 IgA test, the diagnostic sensitivity and specif-
icity were increased to 99% and 96% respectively [62].
The results of immunoprecipitation suggested a direct
interaction between EBNA-5 and p63 protein in NPC, and
this binding would increase the stability of p63. It was
suggested that p63 might be used as an adjunct diagnostic
marker of NPC and contributed a new way to understand
the contribution of the EBV in the pathogenesis of NPC
[63]. Dynamic detection of serum sialic acid and VCA-IgA
might be a valuable technique for diagnosis and monitor-
ing radiotherapy effectiveness in NPC patients. The com-
bined determination of the two indexes could raise the
positive rate of patients with NPC [64]. Poorly differenti-
ated squamous cancer was found to be associated with
EBV antibodies [65]. High-titer antibodies to VCA and
early antigen, especially of high IgA class, or high titers
that persist after therapy, were found to be associated with
a poorer prognosis [66].
The molecular nature of circulating EBV DNA has been
identified as free DNA fragments, and it was not con-
tained inside intact virions. By quantitative size analysis,
Chan and Lo demonstrated that more than 80% of these
DNA fragments were less than 180 bp in size [67]. In the
comparison of EBV DNA levels in plasma and peripheral
blood cell in NPC patients, plasma EBV DNA derived
from the cancer cells was more sensitive and reliable than
peripheral blood cell EBV DNA from circulating mononu-
clear cells for diagnosis, staging and therapeutic effect
evaluation at a molecular level in NPC clinical practice
[68]. The detection of plasma EBV DNA could reflect theMolecular Cancer 2007, 6:1 http://www.molecular-cancer.com/content/6/1/1
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tumours growth and decline. It was an important and sen-
sitive index in diagnosing the residual and relapse of NPC
[69]. Plasma EBV DNA concentration could be used to
predict distant metastasis in NPC. The detecting rates of
both pre-treatment and post-treatment EBV DNA concen-
trations in patients with distant metastasis were signifi-
cantly higher than those with continuous remission and
those with local relapse [70]. The plasma EBV DNA load
was shown to be proportionately related to the presence
of NPC. This finding underscored the prognostic value of
cell-free EBV DNA quantification [71].
There was a study showing that consecutive patients with
metastatic or recurrent NPC receiving combination chem-
otherapy were monitored for EBV DNA in their serum.
Profile of EBV encoded RNA (EBER-1) DNA showed con-
cordance with clinical course of either continuous remis-
sion or later progression. EBER-1 DNA in serum could
become a useful adjunctive surrogate marker to monitor
chemotherapeutic response in NPC patients with distant
metastasis or advanced local recurrence [72]. Differential
expression of EBER and several tumour-related genes were
found in NPC using tissue microarray analysis. EBV infec-
tion, together with overexpression of p53, and loss expres-
sions of p16 and p27 proteins were involved in the
multistep process of human nasopharyngeal epithelial
carcinogenesis [73].
The EBV oncogene BARF1 is expressed in a high propor-
tion of NPC. The structure of the secreted BARF1 glycopro-
tein expressed in a human cell line was solved by X-ray
crystallography. It was most closely related to CD80 or B7-
1, a co-stimulatory molecule present on antigen present-
ing cells, from which BARF1 was derived during evolution
[74]. Measurement of EBV DNA load combined with
BARF1 mRNA detection in simple nasopharyngeal brush-
ings allowed non-invasive NPC diagnosis. It reflected car-
cinoma-specific EBV involvement at the anatomical site of
tumour development and reduced the need for invasive
biopsies. This procedure might be useful for confirmatory
diagnosis in large serological NPC screening program
[75].
In vitro EBV infection resulted in the activation of STAT3
and NF-κB signal cascades in nasopharyngeal epithelial
cells. Increased expression of their downstream targets (c-
Myc, bcl-xL, IL-6, LIF, SOCS-1, SOCS-3, VEGF and COX-2)
was also observed. EBV latent infection induced the sup-
pression of p38-MAPK activities, but did not activate PKR
cascade. These findings suggested that EBV latent infec-
tion was able to manipulate multiple cellular signal cas-
cades to protect infected cells from immunologic attack
and to facilitate cancer development [76]. Measuring the
expression of latent EBV genes in NPC and normal
nasopharyngeal tissue samples, it was shown that deregu-
lation of key proteins involving in apoptosis (bcl-2 related
protein A1 and Fas apoptotic inhibitory molecule), cell
cycle checkpoints (AKIP, SCYL1 and NIN) and metastasis
(matrix metalloproteinase 1) were closely correlated with
the levels of EBV gene expression in NPC [77].
Of the EBV-encoded product, latent membrane protein
LMP-1 is considered to be an oncogene playing an essen-
tial role in cell transformation and metastasis. It is neces-
sary for EBV-induced transformation of B lymphocytes
and is able to transform Rat-1 fibroblasts. LMP-1 can acti-
vate a wide array of signaling pathways, including phos-
phatidylinositol 3-kinase-Akt and NF-κB. It was found
that the signature amino acid changes of the LMP-1 vari-
ants did not hinder or enhance their in vitro transforming
potentials or affect their signaling properties [78]. Comb-
ing the novel strategy of phosphoprotein enrichment with
proteomics technology to elucidate the signaling cascade
activated by LMP-1, annexin A2, heat shock protein 27,
stathmin, annexin I, basic transcription factor 3 and porin
were identified to be novel signaling molecules or targets
with no previously known function in LMP-1 signal trans-
duction [79] (Table 1). Pilot study of LMP-1 and CD99
expressions in NPC suggested that the LMP-1 induced
down-regulation of the CD99 pathway was important in
nasopharyngeal carcinogenesis, and that the expression of
CD99 in lymphoid stroma might regulate immune
response to NPC [80].
LMP-1 played an important role in enhancing NPC cell
response to arsenic trioxide (As2O3). The elongation of
telomere length induced by LMP-1 might contribute to
the mechanisms of As2O3 sensitivity [81]. Preclinical stud-
ies demonstrated that As2O3 could inhibit LMP-1 expres-
sion, dictate apoptosis and alterations of cell cycle
distribution and growth retardation. LMP-1-positive NPC
cells were more sensitive to As2O3 treatment than LMP-1-
negative NPC cells [82]. Further study found that As2O3
could reduce metastatic potential of NPC cells, involving
inhibition of MMP-9 expression. LMP-1 were reduced in
this process and seemed to enhance anti-metastatic activ-
ity of As2O3 [83].
It was suggested that nasopharyngeal swab could be effec-
tive method for gene detection. As a parameter in diagno-
sis of NPC, LMP-1 might be superior to VCA-IgA. Thirty-
bp deletion of LMP-1 was widespread in NPC patients
[84]. The nasopharyngeal swab coupled with PCR based
EBV LMP-1 and EBNA detection could serve as a good
supplement to pathological diagnosis of NPC [85].
EBV-encoded LMP-1 was vulnerable to RNAi and selective
inhibition of LMP-1 had anti-proliferation effect on NPC
cell. RNAi could be a powerful tool in further investiga-
tions of LMP-1 and a novel therapeutic strategy for EBV-Molecular Cancer 2007, 6:1 http://www.molecular-cancer.com/content/6/1/1
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associated NPC patients [86]. A recombinant adeno-asso-
ciated virus type 2 vector was used to deliver shRNA tar-
geting EBV LMP-1  into the EBV-positive human NPC
C666-1 cells. Results demonstrated that long-term sup-
pression of EBV-encoded LMP-1 in vivo is an effective
means for preventing NPC metastasis [87].
Emerging perspectives
Contemporary NPC research has distincted itself from the
traditional one with the unprecedented large amount of
data and tremendous diagnostic and therapeutic innova-
tions. Data are currently generated in high-throughput
fashions with the integration and application of systems
biology. Genomics, proteomics, metabolomics and bioin-
formatics each plays a more and more important role for
molecular biomarker discovery [88]. We now have a bet-
ter understanding of the disease, including its diagnosis,
monitoring, treatment and prognostication. In the era of
molecular targeted therapy, specific treatment to the
potential target using technologies such as immuno-
therapy and RNAi becomes formulating from bench to
bedside application and thus makes molecular biomarker
discovery more meaningful for NPC management.
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